Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00552396 · OUTCOME

Number of Evaluable Patients With Stable Disease. "Evaluable" is Defined as 2 Consecutive M Protein Assessments

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma · Source last updated 2016-03-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Number of participants
Interval / dispersion
Not reported
Time frame
From start of the treatment to end of study or disease progression

What was measured

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

Groups in this outcome

IPH2101 0.0003 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 0.003 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 0.015 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 0.075 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 0.3 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 1 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

IPH2101 3 mg/kg

Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
IPH2101 0.0003 mg/kg1
IPH2101 0.003 mg/kg2
IPH2101 0.015 mg/kg2
IPH2101 0.075 mg/kg5
IPH2101 0.3 mg/kg0
IPH2101 1 mg/kg3
IPH2101 3 mg/kg6

Reported measurements

Source class 1
Values in Number of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
IPH2101 0.0003 mg/kg1Not reportedNot reportedNot reportedNot reported
IPH2101 0.003 mg/kg1Not reportedNot reportedNot reportedNot reported
IPH2101 0.015 mg/kg1Not reportedNot reportedNot reportedNot reported
IPH2101 0.075 mg/kg3Not reportedNot reportedNot reportedNot reported
IPH2101 1 mg/kg2Not reportedNot reportedNot reportedNot reported
IPH2101 3 mg/kg3Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        1
      3. group Id
        OG002
        value
        1
      4. group Id
        OG003
        value
        3
      5. group Id
        OG005
        value
        2
      6. group Id
        OG006
        value
        3
denoms
  1. counts
    1. group Id
      OG000
      value
      1
    2. group Id
      OG001
      value
      2
    3. group Id
      OG002
      value
      2
    4. group Id
      OG003
      value
      5
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      3
    7. group Id
      OG006
      value
      6
    units
    Participants
description
Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
groups
  1. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG000
    title
    IPH2101 0.0003 mg/kg
  2. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG001
    title
    IPH2101 0.003 mg/kg
  3. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG002
    title
    IPH2101 0.015 mg/kg
  4. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG003
    title
    IPH2101 0.075 mg/kg
  5. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG004
    title
    IPH2101 0.3 mg/kg
  6. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG005
    title
    IPH2101 1 mg/kg
  7. description
    Disease Response Assessment by Principal Investigator and Sponsor(Efficacy Population).Stable Disease was defined as not meeting criteria for complete response, very good partial response, partial response, or progressive disease
    id
    OG006
    title
    IPH2101 3 mg/kg
param Type
NUMBER
reporting Status
POSTED
time Frame
From start of the treatment to end of study or disease progression
title
Number of Evaluable Patients With Stable Disease. "Evaluable" is Defined as 2 Consecutive M Protein Assessments
type
SECONDARY
unit Of Measure
Number of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice